Healthcare
Gyre Therapeutics, Inc.(GYRE)
Live Price
Offline$6.25
+2.80% today
1Y Change
-15.65%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $740.00M
- Revenue Growth
- +10.2%
- EPS Growth
- -59.8%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Gyre Therapeutics, Inc. (GYRE) is a Healthcare stock with a market cap of $740.00M and listed on NASDAQ. The stock last traded around $6.25 and down 15.7% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +10.2%, EPS growth of -59.8%, a dividend yield of 0.0%. What stands out right now is revenue +10.2%, EPS -59.8%, free cash flow +97.3% with operating margin 9.9% and ROIC 5.3%. Valuation already assumes a fairly strong business story at P/E 139.3 and price/sales 6.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines GYRE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.2% vs +7.6% peer median
Operating Margin
Below sector median
+9.9% vs +19.4% peer median
P/E
Above sector median
139.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +10.2% and EPS is at -59.8%, with operating margin around 9.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | โ | -5.1% | -12.3% | -19.0% |
2026 Mar 12, 2026 | -29.4% | -3.2% | -12.9% | -5.4% |
2025 Nov 7, 2025 | +20.0% | +9.8% | +10.8% | +13.2% |
Benchmark Edge
GYRE vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GYRE
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GYRE Max Drawdown
-37.32%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GYRE and SPY.
Company Overview
Gyre Therapeutics, Inc.
NASDAQ Capital Market
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
- Leadership
- Ping Zhang
- IPO Date
- Apr 12, 2006
- Employees
- 579
- Street Address
- 12770 High Bluff Drive
- Mailing
- San Diego, CA, 92130
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 619 949 3681
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 139.3
- EV/EBITDA
- 48.2
- Price/Sales
- 6.4
- Price/Book
- 6.6
Growth
- Revenue
- +10.2%
- EPS
- -59.8%
- Free Cash Flow
- +97.3%
Profitability
- Gross Margin
- 95.4%
- Operating Margin
- 9.9%
- Net Margin
- 4.3%
- ROE
- 5.5%
- ROIC
- 5.3%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 5.60
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.